Press release
Data on Early Clinical Benefit for INPEFA® (Sotagliflozin) Will Be Among Five Lexicon-Sponsored Presentations at the American Heart Association Scientific Sessions 2023
Cost-effectiveness data and analyses of financial impact among patients hospitalized for heart failure and treated with INPEFA included as important data
About this update from Lexicon Pharmaceuticals, Inc.
[{"type":"text","content":"Cost-effectiveness data and analyses of financial impact among patients hospitalized for heart failure and treated with INPEFA included as important data selected for presentation INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failure THE WOODLANDS, Texas, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that five data presentations related to INPEFA® (sotagliflozin) will be delivered during the American Heart Association Scientific Sessions 2023, November 11-13, 2023, at the Pennsylvania Convention Center in Philadelphia, PA. Two of the data sets have been selected for oral presentations; one highlighting the early clinical benefit of INPEFA for heart failure and atherosclerotic events, the other focusing on cost-effectiveness metrics associated with the use of INPEFA. “Our significant upcoming presence at the American Heart Association Scientific Sessions 2023 reflects the dedication of investigators to expanding the scientific evidence available to clinicians and payers as they make decisions around how to best utilize available treatment options in patients,” said Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chief medical officer. “We look forward to engaging with attendees and continuing to demonstrate both the clinical and economic value of INPEFA.” Details of the presentations are as follows: Sotagliflozin is associated with early clinical benefit for heart failure and atherosclerotic events – an oral presentation, Sunday, November 12, 2:10 - 2:15 p.m. ET, Zone 2‚ Science and Technology Hall‚ Level 2, presented by Rahul Aggarwal, M.D., Brigham and Women’s Hospital, Boston, MACost-effectiveness of sotagliflozin in heart failure patients with preserved and reduced ejection fractions—results from SOLOIST-WHF – an oral presentation, Sunday, November 12, 12:10 - 12:15 p.m. ET, Zone 2‚ Science and Technology Hall‚ Level 2, presented by William Weintraub, M.D., Medstar Washington Hospital Center, Washington, DCHow will the use of new heart failure treatments impact US health system reimbursement under alternative payment models: Measuring the impact of sotagliflozin use among patients hospitalized for heart failure – an ePoster, Sunday, November 12, 11:30 a.m. - 12:45 p.m. ET, Board #2122, presented by Slaven Sikirica, M.Sc., Lexicon Phar...